Biocon Limited has successfully completed its Qualified Institutions Placement (QIP) issue, raising ₹41,500.00 million through the allotment of equity shares to qualified institutional buyers. The pharmaceutical company's Fund Raising Committee approved the issue and allotment on January 14, 2026, marking the completion of a significant capital raising exercise.

QIP Issue Details

The QIP issue involved the allotment of 11,26,64,585 equity shares of face value ₹5.00 each at an issue price of ₹368.35 per share. The pricing included a premium of ₹363.35 per equity share over the face value.

Impact on Share Capital

Following the successful allotment, Biocon's paid-up equity share capital has increased substantially. The company's total equity base expanded from 1,50,82,43,188 shares to 1,62,09,07,773 shares.

Major Allottees

The QIP witnessed significant participation from prominent mutual fund houses, with several funds receiving substantial allocations. Three major fund groups dominated the allotment, each receiving approximately 29.52% of the total shares offered.

SBI Mutual Fund Group:

• SBI Contra Fund: 1,12,66,460 shares (10.00% of issue)
• SBI Multicap Fund: 97,73,314 shares (8.67% of issue)
• SBI ELSS Tax Saver Fund: 40,72,215 shares (3.61% of issue)
• Other SBI funds received smaller allocations

ICICI Prudential Group:

• ICICI Prudential Value Fund: 1,39,81,271 shares (12.41% of issue)
• ICICI Prudential Pharma Healthcare Fund: 1,05,87,759 shares (9.40% of issue)
• ICICI Prudential Innovation Fund: 32,57,772 shares (2.89% of issue)
• Additional ICICI Prudential funds participated with varying allocations

Mirae Asset Group:

• Mirae Asset Large & Midcap Fund: 38,07,987 shares (3.38% of issue)
• Mirae Asset Large Cap Fund: 26,65,591 shares (2.37% of issue)
• Other Mirae Asset funds received smaller portions

Regulatory Compliance

The QIP was conducted under Chapter VI of the SEBI ICDR Regulations and Sections 23(1)(b), 42 and 62(1)(c) of the Companies Act, 2013. The Fund Raising Committee meeting was held on January 14, 2026, commencing at 11:40 p.m. and concluding at 11:45 p.m.

The trading window for dealing in Biocon securities, which was closed for insiders during the QIP process, is scheduled to reopen on January 17, 2026. The company has submitted the required disclosures to both BSE Limited and National Stock Exchange of India Limited in compliance with SEBI Listing Regulations.

Biocon Limited has announced the approval of its Placement Document for a Qualified Institutions Placement (QIP) of equity shares. The Fund Raising Committee meeting held on January 14, 2026, marked a significant step forward in the company's capital raising initiative.

Committee Meeting Details

The Fund Raising Committee convened on January 14, 2026, with the meeting commencing at 10:12 p.m. and concluding at 10:20 p.m. During this brief but crucial session, the committee approved and adopted the Placement Document dated January 14, 2026, in connection with the proposed equity issue.

Qualified Institutions Placement Structure

The QIP involves equity shares with a face value of ₹5 each. The placement is being conducted under multiple regulatory frameworks to ensure comprehensive compliance. The issue falls under Chapter VI of the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, commonly referred to as the SEBI ICDR Regulations.

Additionally, the placement adheres to specific sections of the Companies Act, 2013, as amended, including:

• Section 23(1)(b)
• Section 42
• Section 62(1)(c)

Regulatory Compliance and Communication

Biocon Limited has fulfilled its regulatory obligations by informing both major stock exchanges about this development. The company communicated with BSE Limited, where its scrip code is 532523, and the National Stock Exchange of India Limited, where it trades under the symbol BIOCON.

The announcement serves as compliance under Regulation 30 and other applicable regulations of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended. The company has also made this information available on its official website at www.biocon.com for public access.

Corporate Communication

The formal communication was signed by Rajesh U. Shanoy, Company Secretary and Compliance Officer, who holds ICSI membership number A16328. The document was digitally signed on January 14, 2026, at 22:27:26 +05'30', ensuring authenticity and regulatory compliance.

This development follows previous communications dated January 12, 2026, and January 14, 2026, indicating ongoing progress in the company's fund-raising activities. The approval of the Placement Document represents a key milestone in Biocon's capital market initiatives.